 |
|
|
| |
Asunaprevir (ASV; BMS-650032), an NS3 Protease Inhibitor, in Combination With Peginterferon and Ribavirin in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C Infection
|
| |
| |
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
Bronowicki J-P,1 Pol S,2 Thuluvath P,3 Larrey D,4 Martorell CT,5 Rustgi VK,6 Morris DW,7 Younes Z,8 Fried MW,9 Bourlière M,10 Hezode C,11 Reddy R,12 Massoud O,13 Abrams GA,14 Ratziu V,15 He B,16 Eley T,16 Ahmad A,16 Cohen D,17 Llamoso C,16 Mendez P,16 Hughes EA16 1Hopital d'Adultes de Brabois, Vandoeuvre les Nancy, France; 2Hopital Cochin, Paris, France; 3Mercy Medical Center, Baltimore, MD, USA; 4Hopital Saint Eloi, Montpellier, France; 5The Research Institute, Springfield, MA, USA; 6Metropolitan Research, Fairfax, VA, USA; 7Healthcare Research Consultants, Tulsa, OK, USA; 8Gastro One, Germantown, TN, USA; 9University of North Carolina School of Medicine, Chapel Hill, NC, USA; 10Hopital Saint Joseph, Marseille, France; 11CHU Henri Mondor, Creteil, France; 12University of Pennsylvania, Philadelphia, PA, USA; 13University of Alabama, Birmingham, AL, USA; 14Alabama Liver & Digestive Specialists, Montgomery, AL, USA; 15Groupe Hospitalier Pitie Salpêtrière, Paris, France; 16Bristol-Myers Squibb, Princeton, NJ, USA; 17Bristol-Myers Squibb, Wallingford, CT, USA
|
| |
|
|
|
|
|
